BTIG lowered the firm’s price target on Renalytix to $4 from $5 . The firm notes that shares of Renalytix declined by 23% following its Q4 report of a very slight revenue miss and following the company’s filing of a $200M shelf offering. BTIG is “surprised” at the magnitude of the move lower on the stock since Renalytix had already publicly communicated to the Street that it planned to raise money to finance its growth initiatives.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RNLX: